Researchers reveal the vulnerability of large language models in medicine.
FDA rejects Regeneron’s bispecific for lymphoma over confirmatory trial status
Regeneron has hit a snag in its attempt to bring a new bispecific antibody to the market, as the FDA rejected odronextamab across two types
March 26, 2024